Abstract 57P
Background
Metabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a target for therapy. The E2F transcription factor-1 (E2F1) regulates metabolic pathways and operates as an oncogene or tumor suppressor as evident by the observation that E2f1-knockout mice develop spontaneous tumors. This discrepancy warrants a detailed investigation how E2F1’s metabolic functions control cellular proliferation and tumor growth.
Methods
Taking advantage of mouse embryonic fibroblasts (MEFs), isolated from E2f1-wild-type (E2f1+/+) and E2f1-knock-out (E2f1-/-) mice as well as transcriptomic profiles (TCGA Pan-cancer study), we investigated the biological outcomes of altered E2F1 expression on glutamine metabolism.
Results
Our data indicate that E2F1 binds the promoter of several glutamine metabolic genes. Interestingly, the gene expression levels of genes in the glutamine metabolic pathway are strongly increased in mouse embryonic fibroblasts lacking E2F1 compared to E2f1+/+ MEFs. In addition, we confirm that E2f1-/- MEFs are more efficient in metabolizing glutamine and producing precursors for proliferation. Mechanistically, we observe a co-occupancy of E2F1 and MYC on glutamine metabolic promoters, increased MYC binding after E2F1 depletion and silencing of MYC decreases the expression of glutamine metabolic genes in E2f1-/- MEFs, suggesting that MYC contributes to increased glutamine metabolic gene expression in E2f1-/- MEFs. These features have also been observed in human patient samples in a screen of 21 different cancer types and showed high relevance in uterine carcinosarcoma and soft tissue sarcomas.
Conclusions
These results confirm increased proliferation upon E2F1 loss, which is dependent on glutamine metabolism. Altogether, our results suggest that E2F1 is a regulator of glutamine metabolism and highlights potentially new targets for cancer interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Pichler and L. Fajas.
Funding
Austrian Science Fund (J4597-B), Swiss National Science Foundation grant (31003A_143369).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
86P - Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
Presenter: Noé Herbel
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Clinical features and genetic profile of MDM2-altered solid tumors
Presenter: Julia Tejerina-Peces
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluation of trending drug targets and technologies in current drug development
Presenter: Matteo Repetto
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Impact of metformin on glucocorticoid-induced changes in systemic metabolism in patients with brain metastases from solid malignancies
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials
Presenter: Jacopo Uliano
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - Molecular predictors of response to the therapy with mitotane in adrenocortical cancer
Presenter: Erika Porubayeva
Session: Cocktail & Poster Display session
Resources:
Abstract
93P - Circulating cell-free DNA fragmentation profiles during systemic therapy of advanced-stage non-small cell lung cancer patients
Presenter: Jelena Milovanovic
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Targeted therapy in pediatric acute myeloid leukemia: An unmet need
Presenter: Banda Teja
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Anticancer activity of Inula recemosa root extract in human liver cancer cell line by attenuation of OCT4/Sox2 axis
Presenter: Tania Ghosh(Sarkar)
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - The Hammersmith score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden
Presenter: James Korolewicz
Session: Cocktail & Poster Display session
Resources:
Abstract